Date:3/2/2010

PITTSBURGH, March 2 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Annual Report on Form 10-K, containing audited consolidated financial statements for the year ended Dec. 31, 2009, as filed with the U.S. Securities and Exchange Commission on Feb. 26, 2010, is available through its Web site (www.mylan.com). In addition, the company's shareholders may receive a hard copy of the Annual Report, free of charge, upon request to Investor Relations at 724-514-1813.

'/>"/>

SOURCE Mylan Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine news :

1. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
2. Mylan Parts Ways with Chief Financial Officer Jolene Varney
3. Mylan Launches First Generic Version of Xopenex(R) Inhalation Solution (Concentrate), 0.25%
4. Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment
5. Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
6. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
7. President Clinton and Mylan Chairman and CEO Robert J. Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries
8. Mylan Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Closing Bell
9. Mylan Announces Enhancements to Executive Management Team
10. Mylan Reports That the FDA Determined That All Accusations Were Unfounded
11. Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality